Vitreous Pharmacokinetics and Retinal Safety of Intravitreal Preserved Versus Non-preserved Triamcinolone Acetonide in Rabbit Eyes

REFERENCES

• Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16:107–123.
   Web of Science ®Google Scholar
• Karla PK, Earla R, Boddu SH, Johnston TP, Pal D, Mitra A. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res. 2009;34:1–9.
   PubMed Web of Science ®Google Scholar
• Fialho SL, Rêgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, Maia-Filho A, Silva-Cunha A. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31:525–534
   PubMed Web of Science ®Google Scholar
• Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Costa RA. Intravitreal injection versus sub-Tenon’s infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845–3849.
   PubMed Web of Science ®Google Scholar
• Lee H, Shah GK. Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina. 2005;25:551–555.
   PubMed Web of Science ®Google Scholar
• Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003;29:27–33.
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmology. 2001;108:765–772.
   PubMed Web of Science ®Google Scholar
• Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277–281.
   PubMedGoogle Scholar
• Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064–1067.
   Google Scholar
• Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003;87:972–974
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Scott IU, Flynn HW, Puliafito CA. Pseudohypopion after triamcinolone acetonide injection for cystoyd macular edema. Am J Ophthalmol. 2004;138:489–492.
   PubMed Web of Science ®Google Scholar
• Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190–195.
   PubMed Web of Science ®Google Scholar
• Naka KI, Rushton WA. S-potentials from luminosity units in the retina of fish (Cyprinidae). J Physiol. 1966;185:587–599.
   PubMed Web of Science ®Google Scholar
• Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lüke M, Spitzer MS, Heide PE, Bartz-Schmidt KU. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol. 2007;245:689–696.
   Google Scholar
• Kim H, Csaky KG, Gravlin L, Yuan P, Lutz RJ, Bungay PM, Tansey G, DE Monasterio F, Potti GK, Grimes G, Robinson MR. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 2006;26:523–530.
   PubMed Web of Science ®Google Scholar
• Oishi M, Maeda S, Hashida N, Ohguro N, Tano Y, Kurokawa N. Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. Jpn J Ophthalmol. 2008;52:489–492.
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Nugent AK, Nomoto H, Sanislo SR, Kitchens JW, Moshfeghi DM. Triamcinolone acetonide preparations: Impact of crystal size on in vitro behavior. Retina. 2009;29:689–698.
   PubMed Web of Science ®Google Scholar
• Missel PJ, Horner M, Muralikrishnan R. Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model. Pharm Res. 2010;27:1530–1546.
   Google Scholar
• Ober MD, Barile GR, Tari SR, Tosi GM, Schiff WM, Chang S. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection. Am J Ophthalmol. 2006;142:597–600.
   Google Scholar
• Scholes GN, O’Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103:1567–1569.
   PubMed Web of Science ®Google Scholar
• Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol. 2006;244:1152–1159.
   PubMed Web of Science ®Google Scholar
• Yu SY, D’Amico FM, Viola F, D’Amico DJ, Young FH. Retinal toxicity of intravitreal triamcinolone acetonide: A morphological study. Retina. 2006;5: 531–536.
   Google Scholar